Abstract Number: 0019 • ACR Convergence 2024
A Novel Product Candidate (CPTX2309) for In Vivo mRNA Engineering of Anti-CD19 CAR T Cells Utilizing Novel CD8-Targeted Lipid Nanoparticles
Background/Purpose: Ex vivo chimeric antigen receptor (CAR) T cell therapies have revolutionized cancer treatment and are demonstrating clinical efficacy in various autoimmune disease indications. Despite…Abstract Number: 0400 • ACR Convergence 2024
Osteoclastogenesis from Peripheral Blood Mononuclear Cells in Children with Chronic Nonbacterial Osteomyelitis Are Similar to Those from Healthy Children
Background/Purpose: Chronic nonbacterial osteomyelitis (CNO) is an autoinflammatory bone disease in which osteoclastogenesis may play a critical role. Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) was shown…Abstract Number: 0524 • ACR Convergence 2024
Evaluating Dose Reduction of Biologic Treatments in Rheumatoid Arthritis: Predicting Flares Using Clinical and Molecular Biomarkers
Background/Purpose: Reducing the dosage of biologic drugs in patients with rheumatoid arthritis (RA) who have achieved remission is a viable and necessary strategy. To identify…Abstract Number: 0606 • ACR Convergence 2024
Choice of Biologic Immunotherapy for Psoriasis or Psoriatic Arthritis Not Associated with Risk of Major Adverse Cardiac Events
Background/Purpose: Individuals with psoriasis or psoriatic arthritis (PsO/PsA) have an elevated risk ofmajor adverse cardiac events (MACE), which include congestive heart failure (CHF), myocardialinfarction (MI),…Abstract Number: 0870 • ACR Convergence 2024
The Impact of Body Mass Index on Cardiovascular Risk in Rheumatoid Arthritis Varies Across Anticitrullinated Protein Antibody Status and Biologic Use
Background/Purpose: The impact of body mass index (BMI) as a surrogate of body fat content on cardiovascular (CV) risk in rheumatoid arthritis (RA) is unclear.…Abstract Number: 1162 • ACR Convergence 2024
Evaluating the Efficacy of Rituximab in the Treatment of Refractory Adult Idiopathic Inflammatory Myositis Using Total Improvement Score: Data from a Real-World Multi-Centre Registry in the United Kingdom
Background/Purpose: B cell depletion in the form of rituximab (RTX) is an established treatment modality for idiopathic inflammatory myopathies (IIM). Treatment response is now assessed…Abstract Number: 1464 • ACR Convergence 2024
Guselkumab and IL-17 Inhibitors Show Comparable Treatment Persistence and Effectiveness in Psoriatic Arthritis: 6-month Interim Results of the PsABIOnd Observational Cohort Study
Background/Purpose: Many drugs are available in PsA and have demonstrated efficacy in randomized controlled trials (RCTs); however, real-world long-term data of drugs are scarce. PsABIOnd…Abstract Number: 1595 • ACR Convergence 2024
Tezepelumab for Relapsing or Refractory Eosinophilic Granulomatosis with Polyangiitis: A European Retrospective Study
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a small vessel vasculitis associated with asthma and blood and tissue eosinophilia. EGPA is often associated with glucocorticoid…Abstract Number: 2028 • ACR Convergence 2024
Therapeutic Insights in VEXAS Syndrome from a Multicenter Study in Spain: Moving Towards Amore Specific and Effective Treatment
Background/Purpose: Nearly four years since its characterization, management and therapeutic algorithms for VEXAS syndrome remain unclear. This study aims to describe treatment approaches and assess…Abstract Number: 2330 • ACR Convergence 2024
Mental Health, Sex, and Comorbidities as Determinants of Recalcitrant PsA
Background/Purpose: Despite significant advances in therapeutics over the past two decades, psoriatic arthritis (PsA) remains difficult to treat, with joint outcomes lagging far behind those…Abstract Number: 2523 • ACR Convergence 2024
Biological Treatment May Be an Option as First Steroid-Sparing Agent in a Subgroup of Young Takayasu Arteritis Patients with Prominent Acute Phase Reactants and Constitutional Symptoms
Background/Purpose: There is no data on which patients biologic immunosuppressive (bIS) treatment should be chosen in Takayasu’s arteritis (TAK). In this study we aimed to…Abstract Number: 0132 • ACR Convergence 2024
Patients with Systemic Autoimmune Rheumatic Diseases Remain at Risk for Hospitalization for COVID-19 Infection in the Omicron Era (2022-2024): A Retrospective Cohort Study
Background/Purpose: The risk of severe acute COVID-19 infection has substantially decreased since the start of the pandemic. However, the risk of severe acute COVID-19 outcomes…Abstract Number: 0405 • ACR Convergence 2024
Olokizumab, a Monoclonal Antibody Against IL-6, in Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA): Results of 24 Weeks of the Phase 2 Open-label Clinical Trial
Background/Purpose: Olokizumab (OKZ) is a direct interleukin-6 inhibitor for treatment of rheumatoid arthritis and is being investigated in the open-label Phase 2 trial in adolescents…Abstract Number: 0526 • ACR Convergence 2024
Comparing Immunogenicity and Safety Following Transition from Reference Rituximab to Biosimilar Rituximab (DRL_RI) in Patients with Rheumatoid Arthritis: A Randomized, Double-blind, Phase 3 Study
Background/Purpose: To assess immunogenicity and safety in patients with active rheumatoid arthritis (RA) transitioning from US-Rituximab (RP) or EU-Rituximab (RMP) to DRL_RI (proposed rituximab biosimilar),…Abstract Number: 0646 • ACR Convergence 2024
Chart Audit of over 1,000 SLE Patients Reveals Biologic Treatment Choice Driven by Disease Manifestations
Background/Purpose: To better understand how US rheumatologists utilize biologics in the management of SLE, especially among those with cutaneous manifestations. No medication is currently FDA-approved…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 54
- Next Page »